Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A patent review (2005 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 5, 2011, Pages 717-796

  Zhan, Peng ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AIDS; drug design; HIV; inhibitors; NNRTIs

Indexed keywords

5 ETHYL 6 METHYL 2 PYRIDINONE; ACETAMIDE DERIVATIVE; AMINE; ANILINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOPHENONE DERIVATIVE; BILR 355; CAPRAVIRINE; CARRAGEENAN; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; GW 678248; HETEROCYCLIC COMPOUND; IDX 899; LERSIVIRINE; MIV 150; MK 4965; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIDINE 1 OXIDE; PYRIMIDINE DERIVATIVE; PYRIMIDINEDIONE DERIVATIVE; PYRROLE DERIVATIVE; RDEA 806; RILPIVIRINE; TRIAZINE DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRX 480773;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING AFFINITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR HYBRIDIZATION; PHYSICAL CHEMISTRY; REVIEW; VIRUS RESISTANCE;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HUMANS; PATENTS AS TOPIC; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955104761     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.568481     Document Type: Review

References (214)

1. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005;48:1297-313 (Pubitemid 40364540)
2. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43 (Pubitemid 40668138)
3. Agrawal L, Lu X, Jin Q, Alkhatib G. Anti-HIV therapy: current and future directions. Curr Pharm Des 2006;12:2031-55 (Pubitemid 43821691)
4. Tronchet JM, Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr Top Med Chem 2003;3:1496-511
5. Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008;15:1083-95 (Pubitemid 352002977)
6. Sweeney ZK, Klumpp K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Discov Devel 2008;11:458-70 (Pubitemid 351950841)
7. Zhou Z, Lin X, Madura JD. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect Disord Drug Targets 2006;6:391-413 (Pubitemid 44890632)
8. Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008;6:427-33
9. Daar ES. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med 2008;16:110-16
10. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-54 (Pubitemid 46380808)
11. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560-5 (Pubitemid 40524478)
12. SUSTIVA ® (efavirenz) capsules and tablets: Package insert, Bristol-Myers Squibb Co., Princeton, NJ, USA ( 2008).Package inserts. Available from: Bms/com/pi/pi-sustiva.pdf
13. Boone LR. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs 2006;7:128-35 (Pubitemid 43230908)
14. Zhan P, Liu X, Fang Z, et al. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5- ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem 2009;44:4648-53
15. Zhan P, Liu X, Fang Z, et al. 1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. Bioorg Med Chem 2009;17:6374-9
16. Zhan P, Liu X, Li Z, et al. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg Med Chem 2009;17:5920-7
17. Zhan P, Liu X, Zhu J, et al. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2009;17:5775-81
18. Zhan P, Liu X, Cao Y, et al. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2008;18:5368-71
19. Zhan P, Liu X, Li Z, et al. 1,2,3-Thiadiazole thioacetanilides. Part 2: synthesis and biological evaluation of a new series of 2-{[4-(3,4- dichlorophenyl)- 1,2,3- thiadiazol-5-yl]sulfanyl}acetanilides as HIV-1 inhibitors. Chem Biodivers 2010;7:1717-27
20. Zhan P, Liu H, Liu X, et al. Synthesis and anti-HIV activity evaluation of novel N§-arylidene-2-[1- (naphthalen-1-yl)-1Htetrazol- 5-ylthio] acetohy drazides. Med Chem Res 2009;19:652-63
21. Liu X, Zhan P, Pannecouque C, De Clercq E. Design, synthesis and anti-HIV-1 evaluation of novel arylazolylthioacetanilides as potent NNRTIS. Antiviral Res 2009;82:A44-5
22. Liu XY, Yan RZ, Wang Y, et al. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydropyrazolo-[ 4,5-e][1,2] thiadiazines. Arch Pharm (Weinheim) 2008;341:216-22
23. Zhan P, Liu X, De Clercq E. Recent advances in antiviral activity of benzo/ heterothiadiazine dioxide derivatives. Curr Med Chem 2008;15:1529-40 (Pubitemid 351997784)
24. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008;134:147-56
25. Alcaro S, Artese A, Ceccherini-Silberstein F, et al. Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. Curr Med Chem 2010;17:290-308
26. Prajapati DG, Ramajayam R, Yadav MR, Giridhar R. The search for potent, small molecule NNRTIs: a review. Bioorg Med Chem 2009;17:5744-62
27. Maddocks S, Dwyer D. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection. Paediatr Drugs 2001;3:681-702 (Pubitemid 32996113)
28. de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010;85:75-90
29. Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 2007;61:105-18
30. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 2004;1:44-64
31. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 1999;54:26-45 (Pubitemid 29187015)
32. Zhan P, Liu X, Li Z. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Curr Med Chem 2009;16:2876-89
33. Chen X, Zhan P, Li D, et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem 2011;18:359-76
34. Medina-Franco JL, Martinez-Mayorga K, Juarez-Gordiano C, Castillo R. Pyridin-2 (1H)-ones: a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors. ChemMedChem 2007;2:1141-7
35. Zhan P, Li Z, Liu X, De Clercq E. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini Rev Med Chem 2009;9:1014-23
36. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005;88:209-31 (Pubitemid 39579659)
37. Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009;16:3903-17
38. Guo H, Kim CU, Kim HS, et al. Preparation of pyrimidinediones as HIV reverse transcriptase inhibitors. WO2008016522; 2008 (Gilead Sciences, Inc., USA; Korea Research Institute of Chemical Technology)
39. Andrews CW III, Cao P, Freeman GA, et al. Preparation of dihydropyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors for treating HIV infection. WO2009020457; 2009
40. He G, Kim CU, Mitchell ML, Xu L. Novel HIV reverse transcriptase inhibitors. WO2009005693; 2009
41. Le VK, Georges B, Hevesi L, et al. Preparation of 2-pyridinone derivatives having HIV inhibiting properties. EP1516873; 2005
42. Kim C, Mitchell ML, Son JC. Pyridone derivatives as non-nucleoside reverse transcriptase inhibitors. WO2010009047; 2010
43. Le VK, Georges B, Hevesi L, et al. 2-Pyridinone derivatives, having HIV inhibiting properties. WO2005028442; 2005
44. Le VK, Georges B, Hevesi L, et al. 2-Pyridinone derivatives, having HIV inhibiting properties. US2007275953; 2007
45. Guillemont JEG, Heeres J, Lewi PJ. Preparation of HIV-inhibiting 5- substituted pyrimidines. WO2006035069; 2006 (Tibotec Pharmaceuticals Ltd, Ire.)
46. Guillemont JEG, Mordant CI. Preparation of HIV inhibiting 5,6-substituted pyrimidines. WO2008080964; 2008 (Tibotec Pharmaceuticals Ltd, Ire.)
47. Guillemont JEG, Mordant CI, Schmitt BA. Preparation of HIV inhibiting 5,6-substituted pyrimidines. WO2008080965; 2008 (Tibotec Pharmaceuticals Ltd, Ire.)
48. Brotherton-Pleiss CE, Kertesz DJ, Yang M. Preparation of piperidinylaminopyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008071587; 2008
49. Kestesz DJ, Brotherton-Pleiss C. Non-nucleoside reverse transcriptase inhibitors. US2008146595; 2008
50. Guillemont J, Emile G. HIV inhibiting 5-amido substituted pyrimidines. US20100168104; 2010
51. De Kock, Herman Augustinus; Wigerinck, Piet Piet Tom Bert Paul. Preparation of HIV inhibiting 2-(4- cyanophenyl)-6- hydroxylaminopyrimidines. WO2006094930; 2006 (Tibotec Pharmaceuticals Ltd, Ire.)
52. Chen F, Xiong Y. Preparation of diaryl-triazine derivatives for treatment of AIDS. CN101265237; 2008
53. Rodgers J, Wang H. 2, 4-Disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors. US6809109; 2004
54. Xie L, Tian X, Li G. The 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside HIV reverse transcriptase, praparation methods and uses thereof. WO2010040275; 2010
55. Xie L, Tian X, Li G. Pyridine derivatives as HIV revertase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infections. CN101717364; 2010
56. Xie L, Qin B, Lee K-H, et al. Substituted diphenylamines as inhibitors of reverse transcriptase, process of preparing them and use thereof. WO2009049491; 2009
57. Guillemont JEG, Paugam M, Delest BFM, et al. HIV inhibiting bicyclic pyrimidine derivatives. WO2006045828; 2006
58. Girardet JL, Koh Y-H, Shaw S, Kin HW. Preparation of purines, azapurines, and deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection. WO2006122003; 2006
59. Girardet JL, Koh Y-H, Shaw S, Kim HW. Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV. US20090124802; 2009
60. Girardet J-L, Hong Z, Shaw S, Koh Y-H. Cyanophenylamino-substituted thienopyrimidine compounds as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use as anti-HIV treatment. WO2008058285; 2008 (Ardea Biosciences, Inc., USA)
61. Jorgensen WL. Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy(HIV). WO2009005811; 2009
62. Jorgensen WL. Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV). US20100168190; 2010
63. Nitz TJ, Salzwedel K, Finnegan C, et al. Anti-HIV compounds. WO2009085256; 2009
64. Jorgensen WL, Ruiz-Caro J, Hamilton AD. Compounds and methods for the treatment of viruses and cancer. WO2007038387; 2007
65. Jones LH, Middleton DS, Mowbray CE, et al. Preparation of phenoxyphenoxyacetamides and related compounds as inhibitors of HIV-1 reverse transcriptase. WO2006067587; 2006 (Pfizer Ltd, UK)
66. Peat AJ, Sebahar PR, Youngman M, et al. Chemical compounds. WO2008154271; 2008
67. Saggar SA, Sisko JT, Tucker TJ, et al. HIV reverse transcriptase inhibitors. US20070021442; 2007
68. Mirzadegan T, Silva T. N-phenyl-phenylacetamide derivatives as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. US2007088053; 2007 (Roche Palo Alto LLC, USA)
69. Silva T, Sweeney ZK. N-phenyl-phenylacetamide derivatives as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. US2007088015; 2007
70. Silva T, Sweeney ZK. N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors. WO2007045572; 2007 (Roche Palo Alto LLC, USA)
71. Dunn JP, Hirschfeld DR, Silva T, et al. Preparation of phenoxyphenylacetamides as non-nucleoside reverse transcriptase inhibitors. US2005239881; 2005
72. Dunn JP, Hirschfeld DR. Use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections. US2005239880; 2005
73. Dunn JP, Hirschfeld DR, Silva T, et al. Non-nucleoside reverse transcriptase inhibitors. WO2005102989; 2005. (Roche Palo Alto LLC, USA)
74. Sweeney ZK. Preparation of 2-(3-phenoxyphenoxy)-N-phenylacetamide derivatives for treatment of AIDS. WO2008009613; 2008
75. Peat AJ, Sebahar PR, Youngman M, et al. Preparation of N- (cyanophenoxybenzyl) (hetero)aryl carboxamides as a non-nucleoside reverse transcriptase inhibitors for treating HIV infection. WO2008154271; 2008
76. Wu B, Nguyen TN, Ellis DA, et al. Preparation of phenoxyphenylpyrrolidones for treatment of HIV infection. WO2006081554; 2006
77. Dunn JP, Elworthy TR, Hogg JH, Stefanidis D. Preparation of benzyl pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors. WO2005090317; 2005
78. Dunn JP, Dymock BW, Mirzadegan T, et al. Non-nucleoside reverse transcriptase inhibitors. US20040198736; 2004
79. Kennedy-Smith J, Sweeney ZK, Wu J. Diazacyclic derivatives as non-nucleoside reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008145562, 2008
80. Kennedy-Smith J, Sweeney ZK, Wu J. Non-nucleoside reverse transcriptase inhibitors. US2009076045; 2009
81. Saito YD, Smith M, Sweeney ZK. Preparation of heterocyclic non-nucleoside reverse transcriptase inhibitors. US2007078128; 2007 (Roche Palo Alto LLC, USA)
82. Dunn JP, Elworthy TR, Stefanidis D, Sweeney ZK. Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. WO2006010545; 2006 (F. Hoffmann-La Roche AG, Switz.)
83. Sweeney ZK, Welch M. Substituted [1,2,4]-triazoles as non-nucleoside reverse transcriptase inhibitors and their preparation and use for prevention and treatment of HIV-1 infections. WO2008119662; 2008 (F. Hoffmann-La Roche A.-G., Switz.)
84. Martin M, Vora HU. Heterocyclic reverse transcriptase inhibitors. US20060223874; 2006
85. Martin M, Vora H. Preparation of 1,2,4-triazole-5-ones as reverse transcriptase inhibitors for treatment of AIDS or ARC. WO2006099978; 2006 (F.Hoffmann-La Roche A.-G., Switz.)
86. Dunn JP, Swallow S, Sweeney ZK, et al. Nonnucleoside reverse transcriptase inhibitors. US20070179157; 2007
87. Aquino CJ, Dickson H, Peat AJ. Preparation of 1,3,4-oxadiazoles as a non-nucleoside reverse transcriptase inhibitor for treating human immunodeficiency virus infection. WO2008157330; 2008 (SmithKline Beecham Corp., USA)
88. Aquino CJ, Dickson H. Chemical compounds. WO2008157273; 2008
89. Billedeau RJ, Palmer WS, Sweeney ZK, Wu J. Preparation of pyridazine derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008122534; 2008 (F. Hoffmann-La Roche A.-G., Switz.)
90. Billedeau RJ, Palmer W, Sweeney ZK, Wu J. Non-nucleoside reverse transcriptase inhibitors. US2008293664; 2008
91. Billedeau RJ, Sweeney ZK. Heterocyclic antiviral compounds. WO2009080534; 2009
92. Billedeau RJ, Sweeney ZK. Heterocyclic antiviral compounds. US2009170856; 2009
93. Elworthy TR, Hogg JH, Kennedy-Smith J, et al. Preparation of urea and carbamate derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. WO2009000663; 2009
94. Elworthy TR, Hogg JH, Kennedy-Smith J, et al. Non-nucleoside reverse transcriptase inhibitors. US2009012034; 2009 (F. Hoffmann-La Roche A.-G., Switz.)
95. Kennedy-Smith J, Palmer WS, Sweeney ZK. Preparation of phenoxybenzene derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008019968; 2008 (F. Hoffmann-La Roche AG, Switz.)
96. Saggar SA, Sisko JT, Tucker TJ, et al. Preparation of heterocyclic phenoxy compounds as HIV reverse transcriptase inhibitors. US2007021442; 2007 (Merck & Co., Inc., USA)
97. Anthony NJ, Gomez R, Jolly SM. 1- (1H-Pyrazolo[3,4-b]pyridin-3-ylmethyl)- 1H-indazole derivatives as non-nucleoside reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008076223; 2008 (Merck & Co., Inc., USA)
98. Anthony NJ, Gomez R, Jolly SM, et al. Preparation of substituted indazoles, benzotriazoles and related bicyclic compounds as non-nucleoside reverse transcriptase inhibitors. WO2008076225; 2008 (Merck & Co., Inc., USA)
99. Anthony NJ, Gomez R, Jolly SM, et al. Non-nucleoside reverse transcriptase inhibitors. US2008275097; 2008
100. Tucker TJ, Tynebor R, Sisko JT, et al. Non-nucleoside reverse transcriptase inhibitors. WO2009067166; 2009
101. Arora N, Billedeau RJ, Kennedy-Smith J, et al. Pyridine derivatives as inhibitors of HIV-1 reverse transcriptase. WO2010026075; 2010
102. Arora N, Billedeau RJ, Kennedy-Smith J, et al. Inhibitors of HIV-1 reverse transcriptase. US2010056535; 2010
103. Andrews CW III, Chan JH, Freeman GA, et al. Benzophenones as inhibitors of reverse transcriptase. US7273863; 2007
104. Bonneau P, Deroy P, Gagnon A, et al. Preparation of phenylalkyne derivatives as non nucleoside reverse transcriptase inhibitors for treatment of HIV infection. US2006069261; 2006 (Boehringer Ingelheim International GmbH, Germany)
105. Simoneau B, O'Meara J, Yoakim C. Preparation of acylaminobenzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors. US2006025480; 2006 (Boehringer Ingelheim International G.m.b.H., Germany)
106. Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3- chloro- 5-cyanophenyl)carbonyl]phenyl}oxy)-N- (4-{[(2S)-2,3-dihydroxy-3- methylbutyl} oxy}-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121415; 2007
107. Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3- chloro- 5-cyanophenyl)carbonyl]phenyl}oxy)-N- {3-fluoro-4-[(2-hydroxy-2- methylpropyl) oxy]-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121418; 2007
108. Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3- chloro- 5-cyanophenyl)carbonyl]phenyl}oxy)-N- {4-[(2,3-dihydroxy-3-methylbutyl) oxy]-3- fluoro-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121416; 2007 (Smithkline Beecham Corp., USA)
109. Girardet J-L, Zhang Z, Hamatake R, et al. Non-nucleoside reverse transcriptase inhibitors. WO2004030611; 2004
110. Simoneau B, Thavonekham B, Landry S, et al. Non-nucleoside reverse transcriptase inhibitors. WO2004050643; 2004
111. Simoneau B, Faucher A-M, Landry S, et al. Non-nucleoside reverse transcriptase inhibitors. US2005054639; 2005
112. Deroy P, Faucher A-M, Gagnon A, et al. Non-nucleoside reverse transcriptase inhibitors. US20090143370, 2009
113. Deroy P, Faucher A-M, Gagnon A, et al. Preparation of acetamide derivatives as reverse transcriptase inhibitors for treatment of HIV. (Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG).WO2005118575; 2005
114. Shaw-Reid CA, Miller MD, Hazuda DJ, et al. Preparation of tetrazolyl derivatives as HIV reverse transcriptase inhibitors. WO2005115147; 2005 (Merck & Co., Inc., USA; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.)
115. Girardet J-L, Koh Y-H, De la Rosa M, et al. Preparation of S-triazolyl alphamercaptoacetanilides as inhibitors of HIV reverse transcriptase. WO2006026356; 2006 (Valeant Research & Development, USA)
116. Girardet J-L, Koh Y-H, De la Rosa M, et al. S-Triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. US20080176850, 2008
117. Girardet J-L, Koh Y-H. 2-(5-Bromo-4- (4-cyclopropylnaphthalen-1-yl)-4h-1, 2,4- triazol-3-ylthio)acetic acid and methyl ester. US20100081827; 2010
118. Girardet J-L, Koh Y-H, De la Rosa M, et al. N[S(4-aryl-triazol-3-yl) alphamercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors. US20100137590; 2010
119. Girardet J-L, Koh Y-H, De la Rosa M, et al. N[S(4-aryl-triazol-3-yl) alphamercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors. US20080319201; 2008
120. Girardet J-L, Koh Y-H, De la Rosa M, et al. Preparation of S-triazolyl alphamercaptoacetanilides as inhibitors of HIV reverse transcriptase. US2006270725; 2006 (Valeant Research & Development, USA)
121. Koch U, Kinzel O, Muraglia E, Summa V. Preparation of N-Ph dicarbamate derivatives as HIV reverse transcriptase inhibitors. WO2006037468; 2006 (Istituto di Ricerche di Biologia Molecolare P Angeletti S.p.A., Italy)
122. Olson MW, Di Grandi M, Prashad A. Carbamates as HIV anti-viral agents. US2005203176; 2005 (Wyeth, John, and Brother Ltd, USA)
123. Su D-S, Anthony NJ, Lim JJ, et al. Preparation of tetrahydroquinolines and related compounds as reverse transcriptase inhibitors. WO2007146230; 2007 (Merck & Co., Inc., USA)
124. Antonov D, Sund C, Lindstroem S, Sahlberg C. Preparation of pyridinyl (thio)urea derivatives of cyclopropachromenes, cyclopropaindenes, cyclopropanaphthalenes, and benzocyclopropacycloheptenes as non-nucleoside reverse transcriptaseinhibitors. WO2004021969; 2004 (Medivir Ab, Sweden)
125. Sund C, Roue N, Lindstroem S, et al. Non-nucleotide reverse transcriptase inhibitors. WO2005066131; 2005
126. Williams TM, Zhang X-F. Preparation of indolecarboxylates and -carboxamides as HIV reverse transcriptase inhibitors. WO2007021629; 2007 (Merck & Co., Inc., USA)
127. Williams TM, Zhang X-F. Non-nucleoside reverse transcriptase inhibitors. US2009131494; 2009
128. Wolkenberg SE, Zhao Z, Lindsley CW. Preparation of indolesulfonamides as non-nucleoside HIV reverse transcriptase inhibitors for the treatment of HIV infection and AIDS. WO2007002368; 2007 (Merck & Co., Inc., USA)
129. Lindsley CW, Leister WH, Wolkenberg SE. Preparation of sulfonylindoles as non-nucleoside HIV reverse transcriptase inhibitors for the treatment of HIV infection and AIDS. WO2007002481; 2007 & US20100179122; 2010 (Merck & Co., Inc., USA)
130. Wolkenberg SE, Lindsley CW, Zhao Z, Williams TM. Preparation of indole derivatives as non-nucleoside reverse transcriptase inhibitors. WO2007002458; 2007 & US20100168097; 2007 (Merck & Co., Inc., USA)
131. Storer R, Alexandre F-R, Dousson C, et al. Enantiomerically pure phosphoindoles as HIV inhibitors. WO2008042240; 2008
132. Storer R, Dousson C, Alexandre F-R, Roland A. Preparation of phospho-indoles as HIV inhibitors. US2006074054; 2006 (Idenix Pharmaceuticals, Inc., USA)
133. Yoakim C, O'Meara J, Simoneau B, et al. Preparation of 9H-imidazo[1,2-d] dipyrido[2,3-b: 3¢,2¢-f][1,4]diazepine derivatives as tetracyclic non-nucleoside reverse transcriptase inhibitors useful against wild type and double-mutation K103N/Y181C enzymes. WO2004026875; 2004 (Boehringer Ingelheim (Canada) Ltd, Canada)
134. Gant TG, Sarshar S. Preparation of deuterium-incorporated cyclopropyldipyridodiazepinone derivatives for use as non-nucleoside reverse transcriptase inhibitors. WO2008103899; 2008 (Auspex Pharmaceuticals, Inc., USA)
135. Meyer O, Heddesheimer I, Zerban G. Process for preparation of diazepine N-oxide derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. WO2006048425; 2006 (Boehringer Ingelheim Pharma Gmbh & Co. KG, Germany)
136. Jones LH, Newman SD, Swain NA. Preparation of 3-chloro-5-cyano thiophenyl substituted imidazole derivatives as HIV-1 reverse transcriptase inhibitors and modulators. WO2006072833; 2006 (Pfizer Ltd, UK)
137. Jones LH, Mohammed S, Mowbray CE, et al. Sulfur-linked imidazole compounds for the treatment of HIV. WO2005100322; 2005 (Pfizer Ltd, UK; Pfizer, Inc.)
138. Jones LH, Mowbray CE, Price DA, et al. Pyrazole derivatives. US2005004129; 2005
139. Cushman MS, Sakamoto T, Cullen MD. Alkenyldiarylmethanes having nitrogen-containing carboxylic acid derivatives as non-nucleoside inhibitors of HIV-I reverse transcriptase. WO2008119028; 2008
140. Cushman MS, Deng B-L. Preparation of alkenyldiarylmethanes and fused analogs as inhibitors of HIV-I reverse transcriptase. WO2007005531; 2007
141. Cushman MS, Deng B-L. Alkenyldiarylmethanes, fused analogs and syntheses thereof. US2008300288; 2008
142. Williams TM, Zhang X-F, Obligado VE, Poehnelt RA. Preparation of pyrrole carboxamides as non-nucleoside reverse transcriptase inhibitors. PCT Int Appl 2008:109. CODEN: PIXXD2 WO2008054605 A2
143. Williams TM, Zhang X-F, Obligado VE, Poehnelt RA. Non-nucleoside reverse transcriptase inhibitors. US20100113421; 2010 (Merck & Co., Inc., USA)
144. Olson M, Di GM. Preparation of triazole derivatives for treating HIV infections. US2005209287; 2005
145. Botta M, Corelli F, Petricci E, et al. Preparation of pyrimidine and pyrimidinone derivatives and their use for the treatment of HIV infections. WO2007043094; 2007
146. Kesteleyn BRR, Van De Vreken W, Surleraux DLNG, et al. Preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-2-ones as inhibitors of HIV reverse transcriptase. WO2005111044; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
147. Kesteleyn BRR, Raboisson PJ-MB, Surleraux DLNG, et al. Preparation of 1- heterocyclyl-1,5-dihydropyrido[3,2-b] indol-2-ones and analogs as antiviral agents. WO2005111047; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
148. Kesteleyn BRR, Vendeville SMH, Kindermans NMF, et al. Preparation of 1-phenyl-1,5-dihydropyrido[3,2-b]indol- 2-ones and analogs as antiviral agents. WO2005111035; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
149. Kesteleyn BRR, Vendeville SMH, Kindermans NMF, et al. Preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compositions for the treatment of HIV-infection. WO2005110411; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
150. Kesteleyn BRR, Canard MFJ-MG, Van De Vreken W, et al. Preparation of 1-phenyl-1, 5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents. WO2005111034; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
151. Olson M, Di Grandi M, Prashad A. Preparation of 1,2-dihydroquinoline derivatives as inhibitors of RNase H and HIV reverse transcriptase. US2005203129; 2005
152. Elleder D, Young JAT, Baiga TJ, Noel JP. Non-nucleoside reverse transcriptase inhibitors. WO2009061856; 2009
153. Bode ML, Rousseau AL, Gravestock D, et al. Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors. WO2010032195; 2010
154. Anderson KS, Hunter R. Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase. WO2009126293; 2009
155. Hannongbua S. Structural information and drug-enzyme interaction of the non-nucleoside reverse transcriptase inhibitors based on computational chemistry approaches. Top Heterocycl Chem 2006;4:55-84
156. Pornpan P, Punkvang A, Saparpakorn P, et al. Recent advances in NNRTI design: computer-aided molecular design approaches. Current Computer Aided Drug Design 2009;5:174-99
157. Pettersson S, Clotet-Codina I, Este JA, et al. Recent advances in combinatorial chemistry applied to development of anti-HIV drugs. Mini Rev Med Chem 2006;6(1):91-108
158. Wyatt PG, Bethell RC, Cammack N, et al. Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J Med Chem 1995;38:1657-65
159. Wang Z, Wu B, Kuhen KL, et al. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 nonnucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2006;16:4174-7
160. De La Rosa M, Kim HW, Gunic E, et al. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006;16:4444-9 (Pubitemid 44094093)
161. Muraglia E, Kinzel OD, Laufer R, et al. Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg Med Chem Lett 2006;16:2748-52
162. Jiang T, Kuhen KL, Wolff K, et al. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. Bioorg Med Chem Lett 2006;16:2105-8 (Pubitemid 43351059)
163. Krajewski K, Zhang Y, Parrish D, et al. New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett 2006;16:3034-8
164. Wu B, Kuhen K, Ngoc Nguyen T, et al. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1. Bioorg Med Chem Lett 2006;16:3430-3 (Pubitemid 43777108)
165. Masuda N, Yamamoto O, Fujii M, et al. Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: design and synthesis of thiazolidenebenzenesulfonamides. Bioorg Med Chem 2004;12:6171-82 (Pubitemid 39445356)
166. Moyle G, Boffito M, Stoehr A, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother 2010;54(8):3170-8
167. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27
168. Zhou XJ, Pietropaolo K, Damphousse D, et al. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009;53:1739-46
169. Klibanov OM, Kaczor RL. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010;11:237-45
170. Romines KR, Freeman GA, Schaller LT, et al. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 2006;49:727-39 (Pubitemid 43157502)
171. Hazen RJ, Harvey RJ, St Clair MH, et al. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother 2005;49:4465-73 (Pubitemid 41552574)
172. Ferris RG, Hazen RJ, Roberts GB, et al. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2005;49:4046-51 (Pubitemid 41400945)
173. de Serres M, Moss L, Sigafoos J, et al. The disposition and metabolism of GW695634: a non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS. Xenobiotica 2010;40:437-45
174. Fatkenheuer G, Staszewski S, Plettenburg A, et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 2009;23:2115-22
175. Corbau R, Mori J, Phillips C, et al. Lersivirine: a non-nucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus-1. Antimicrob Agents Chemother 2010;54:4451-63
176. Tucker TJ, Sisko JT, Tynebor RM, et al. Discovery of 3-{5-[(6-amino-1H- pyrazolo [3,4-b]pyridine-3-yl)methoxy]-2- chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse
177. Lai MT, Munshi V, Touch S, et al. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009;53:2424-31
178. Fernandez-Romero JA, Thorn M, Turville SG, et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007;34:9-14 (Pubitemid 46041501)
179. O'Meara JA, Yoakim C, Bonneau PR, et al. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors. J Med Chem 2005;48:5580-8 (Pubitemid 41209255)
180. Huang F, Koenen-Bergmann M, Macgregor TR, et al. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2008;52:4300-7
181. Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem Rev 1996;96:3147-76 (Pubitemid 126641132)
182. Olesen PH. The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 2001;4:471-8 (Pubitemid 32678536)
183. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49 (Pubitemid 40089827)
184. Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:1829-52 (Pubitemid 47163402)
185. Terasaka T, Kinoshita T, Kuno M, Nakanishi I. A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004;126:34-5 (Pubitemid 38090326)
186. Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98).Lancet 2000;355:1022
187. Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov Today 2009;14:516-22
188. Patel Y, Gillet VJ, Bravi G, Leach AR. A comparison of the pharmacophore identification programs: catalyst, DISCO and GASP. J Comput Aided Mol Des 2002;16:653-81 (Pubitemid 36204617)
189. Iwase K, Hirono S. Estimation of active conformations of drugs by a new molecular superposing procedure. J Comput Aided Mol Des 1999;13:499-512 (Pubitemid 29395564)
190. Daeyaert F, de Jonge M, Heeres J, et al. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins 2004;54:526-33 (Pubitemid 38197364)
191. Daszykowski M, Walczak B, Xu QS, et al. Classification and regression trees - studies of HIV reverse transcriptase inhibitors. J Chem Inf Comput Sci 2004;44:716-26
192. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004;2:323-32 (Pubitemid 39242962)
193. Esnouf RM, Ren J, Hopkins AL, et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 1997;94:3984-9 (Pubitemid 27180485)
194. Duarte CD, Barreiro EJ, Fraga CA. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 2007;7(11):1108-19
195. Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov Today 2007;12:149-55 (Pubitemid 46188408)
196. D'Cruz OJ, Uckun FM. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 2006;4:329-45 (Pubitemid 44027722)
197. Zhou Z, Madrid M, Evanseck JD, Madura JD. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J Am Chem Soc 2005;127:17253-60 (Pubitemid 41794061)
198. Zhan P, Liu X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des 2009;15:1893-917
199. Tucker TJ, Saggar S, Sisko JT, et al. The design and synthesis of diaryl ether second generation NNRTIs with enhanced potency versus key clinical mutations. Bioorg Med Chem Lett 2008;18:2959-66 (Pubitemid 351622042)
200. Zhan P, Li Z, Liu X. Cosalane and its analogues: a unique class of anti-HIV agents. Mini Rev Med Chem 2010;10:966-76
201. Silva ATA, Castro LF, Guido RVC, et al. Advances in prodrug design. Mini Rev Med Chem 2005;5:893-914 (Pubitemid 41300737)
202. Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404 (Pubitemid 38580074)
203. Elworthy TR, Dunn JP, Hogg JH, et al. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2008;18:6344-7
204. Chen JM, Chen X, Kim CU, et al. Non nucleoside reverse transcriptase inhibitors. US2006128692; 2006
205. Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem 2008;51:2432-8 (Pubitemid 351628504)
206. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90 (Pubitemid 350042396)
207. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-5
208. Gewurz BE, Jacobs M, Proper JA, et al. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis 2004;190:1957-61 (Pubitemid 39564701)
209. Sato A, Hammond J, Alexander TN, et al. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res 2006;70:66-74
210. Mowbray CE, Burt C, Corbau R, et al. Pyrazole NNRTIs 1: design and initial optimisation of a novel template. Bioorg Med Chem Lett 2009;19:5599-602
211. Mowbray CE, Corbau R, Hawes M, et al. Pyrazole NNRTIs 3: optimization of physicochemical properties. Bioorg Med Chem Lett 2009;19:5603-6
212. Mowbray CE, Burt C, Corbau R, et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett 2009;19:5857-60
213. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl] amino]-2- pyrimidinyl]amino] benzonitrile (R278474, rilpivirine). J Med Chem 2005;48(6):1901-9
214. Kilby JM, Saag MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect Agents Dis 1994;3:313-23